Scynexis Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SCYNEXIS, and when can generic versions of SCYNEXIS drugs launch?
SCYNEXIS has one approved drug.
There are five US patents protecting SCYNEXIS drugs.
There are thirty-eight patent family members on SCYNEXIS drugs in twenty-four countries.
Drugs and US Patents for Scynexis
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | 10,174,074 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | 10,370,406 | ⤷ Sign Up | ⤷ Sign Up | ||||
Scynexis | BREXAFEMME | ibrexafungerp citrate | TABLET;ORAL | 214900-001 | Jun 1, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Scynexis Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Finland | 3661503 | ⤷ Sign Up |
Slovenia | 3661503 | ⤷ Sign Up |
European Patent Office | 2326181 | ⤷ Sign Up |
Mexico | 2020001399 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.